The app for independent voices
FDA Approved Pfizer Drug Panzyga to Treat Serious COVID-19 Vaccine Side Effect Just Two Months After Rollout of COVID-19 Vaccines. By ICAN Legal (08/19/25)
How very convenient for Pfizer…
FDA’s approval of Pfizer’s drug Panzyga for treating Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a rare neurological autoimmune condition, occurred just in the nick of time. CIDP is a known side effect of COVID-19 shots and Panzyga was approved just two months after shot rollout. (CIDP is similar to another COVID-19 shot adverse reaction: Guillain-Barré syndrome.)This leads to burning questions:
Were Pfizer and the FDA aware of potential neurological risks connected to COVID-19 vaccines, given that CIDP has since been identified as a serious adverse reaction in some cases?
Is drug regulation really transparent?
Summary (ChatGPT, edited)
Pfizer’s Application and FDA Approval
April 2020: Pfizer applied to the FDA to market Panzyga for CIDP, before COVID-19 vaccine human trials began.
February 12, 2021: FDA granted approval, just two months after COVID-19 vaccines rolled out in the U.S.
Suspicion Raised: The timing suggests FDA may have observed early vaccine safety signals pointing to neurological risks.
Concerns About Neurological Reactions
CIDP and Vaccines: CIDP is a known serious adverse reaction to mRNA vaccines.
Preclinical Data: Had Pfizer’s own early animal trials already hinted at neurological issues?
Notable Cases:
Maddie de Garay – Injured during Pfizer’s trial for ages 12–15.
Brianne Dressen – Injured during AstraZeneca’s adult trial.
Legal and Investigative Actions
ICAN Attorneys: Legal representatives have requested all FDA documents tied to Panzyga’s approval for CIDP.
Objective: To uncover whether regulatory agencies and Pfizer were aware of potential risks earlier than disclosed.
Conclusion
ICAN Legal raises doubts about the relationship between Pfizer’s drug approval, vaccine rollout, and emerging adverse neurological reactions. It underscores the need for transparency in regulatory decisions and ongoing legal efforts to investigate possible conflicts of interest or withheld data.
Related:
Panzyga FDA Approval and Package Insert: tinyurl.com/yycz56u2
Cleveland Clinic: CIDP (Chronic Inflammatory Demyelinating Polyneuropathy): tinyurl.com/4v7x6z22
OpenVAERS Search:
